Market Volatility
Could reduce demand for foam glass products
- Materiality
- high
Foamit Oyj
Partnera is a Finnish investment company focusing on developing and managing its portfolio companies. It holds a 100% ownership in Foamit Group, which specializes in the production and sale of foam glass products. Partnera is actively involved in strategic investments and divestments to optimize its portfolio and enhance shareholder value. The company operates primarily in the Nordic region, with a focus on infrastructure and environmental solutions.
| % | |
|---|---|
| Foam Glass Products | 80% Includes foam glass for infrastructure and environmental projects |
| Investment Management | 15% Strategic management of portfolio investments |
| Divestments | 5% Sale of non-core assets to optimize portfolio |
Partnera's customers primarily include public sector entities and large construction companies in the Nordic region...
- Public Sectorprimary
Buys foam glass for infrastructure projects due to sustainability
- Construction Companiesprimary
Use foam glass for lightweight construction needs
- Packaging Industrysecondary
Requires sustainable glass solutions
- Institutional Investorsemerging
Seek strategic investment management services
Partnera operates primarily in the Nordic region, with significant activities in Finland, Norway, and Sweden...
- •Operations primarily in Finland, Norway, and Sweden
- •Manufacturing facilities located in Norway and Finland
- •Key markets are Nordic countries focused on sustainability
- •Strategic investments extend to other European regions
Partnera's strategic priorities include expanding its foam glass business and optimizing its investment portfolio...
01
Expand Foam Glass Businessmedium-term
To increase market share and revenue
02
Optimize Investment Portfolioshort-term
To improve financial performance
03
Strategic Acquisitionslong-term
To grow portfolio value
Partnera faces several risks, including market volatility and geopolitical uncertainties that could impact demand for...
Supply Chain Disruptions
Affect production and delivery schedules
- Materiality
- high
Geopolitical Uncertainties
Impact on operations and investment decisions
- Materiality
- medium
Financial Risks
Interest rate and currency fluctuations affect costs
- Materiality
- medium
Regulatory Changes
Increase compliance costs and operational adjustments
- Materiality
- medium
Revenue Recognition
Seasonal Fluctuations
Estimates and Provisions
IFRS 16
Lease Accounting (IFRS 16)
Phathom Pharmaceuticals, Inc.
PHAT · Pharmaceutical Preparations
Phathom Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing vonoprazan-based therapies for acid-related gastrointestinal diseases.
SOLIGENIX, INC.
SNGX · Pharmaceutical Preparations
Verastem, Inc.
VSTM · Pharmaceutical Preparations
BIOMARIN PHARMACEUTICAL INC
BMRN · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Sagimet Biosciences Inc.
SGMT · Pharmaceutical Preparations
: 11/08/2026